An immunoconjugate anticancer drug
consists of a tumor-targeting monoclonal
antibody  a manufactured protein created
to bind specifically to a target found on
cancer cells  with an attached cell-killing,
or cytotoxic, agent. The antibody componentenables the immunoconjugate to bindspecifically to the cancer cells that have its
target on their surface and the cytotoxic
agent serves to kill the cancer cells.

TAP compounds are designed to travel through a patients bloodstream to reach the target cancer cells wherever they occur.